Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
ACLX is expected to report earnings to fall 10.98% to -88 cents per share on February 26
Q4'25
Est.
$-0.88
Q3'25
Missed
by $0.03
Q2'25
Beat
by $0.08
Q1'25
Missed
by $0.37
Q4'24
Missed
by $0.31
The last earnings report on November 05 showed earnings per share of -99 cents, missing the estimate of -95 cents. With 341.38K shares outstanding, the current market capitalization sits at 5.21B.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. ACLX showed earnings on November 05, 2025. You can read more about the earnings report here.